The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
LatchBio
Provides biocomputational infrastructure to accelerate laboratory data analysis workflows.
What they do
The company builds web-based software that allows biologists to upload, organize, and analyze genomic sequencing data without writing code. Biotechnology companies and academic labs use the software to run pipelines.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- Bioinformatics platform
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- San Francisco, United States
- Region
- North America
- Founded
- 2021
- Total funding
- $33M raised
Notable investors: Coatue, Lux Capital, Hummingbird Ventures, Y Combinator.
Also in Biotech & Pharma
Related on The Signal
Dr. Dereck Mush, MD, MBA
The biotech IPO window is reopening, cautiously, and the terms have changed
Dr. Dereck Mush, MD, MBA
Precision fermentation is quietly becoming a supply chain strategy for biotech, not just a food tech story
Dr. Dereck Mush, MD, MBADecentralized and adaptive trial designs move from pilot to default in biotech development plans
Dr. Dereck Mush, MD, MBA